Hubbry Logo
AkathisiaAkathisiaMain
Open search
Akathisia
Community hub
Akathisia
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Akathisia
Akathisia
Akathisia
View on Wikipedia
from Wikipedia

Akathisia
Other namesAcathisia
Common sign of akathisia
SpecialtyNeurology, psychiatry
SymptomsFeelings of restlessness, inability to stay still, uneasy[1]
ComplicationsViolence or suicidal thoughts[2]
DurationShort- or long-term[2]
CausesAntipsychotics, selective serotonin reuptake inhibitors, metoclopramide, reserpine[2]
Diagnostic methodBased on symptoms[2]
Differential diagnosisAnxiety, tic disorders, tardive dyskinesia, dystonia, medication-induced parkinsonism, restless leg syndrome[2][3]
TreatmentReduce or switch antipsychotics, correct iron deficiency,[2] exercise
MedicationDiphenhydramine, gabapentin, trazodone, benzodiazepines, benztropine, mirtazapine, beta blockers[4][2]
FrequencyRelatively common[4]

Akathisia (/æ.kə.ˈθɪ.si.ə/ a-kə-THI-see-ə) is a movement disorder[5] characterized by a subjective feeling of inner restlessness accompanied by mental distress and/or an inability to sit still.[6][4] Usually, the legs are most prominently affected.[2] Those affected may fidget, rock back and forth, or pace,[7] while some may just have an uneasy feeling in their bodies.[2] The most severe cases may result in poor adherence to medications, exacerbation of psychiatric symptoms, and, because of this, aggression, violence, and/or suicidal thoughts.[2] Akathisia is also associated with threatening behaviour and physical aggression in mentally disordered patients.[8] However, the attempts to find potential links between akathisia and emerging suicidal or homicidal behaviour were not systematic and were mostly based on a limited number of case reports and small case series.[9] Apart from these few low-quality studies, there is another more recent and better quality study (a systematic review from 2021)[9] that concludes akathisia cannot be reliably linked to the presence of suicidal behavior in patients treated with antipsychotic medication.[9]

Antipsychotic medication, particularly the first generation antipsychotics, are a leading cause.[4][7] Other agents commonly responsible for this side-effect may also include selective serotonin reuptake inhibitors, metoclopramide, and reserpine, though any medication listing agitation as a side effect may trigger it.[2][10] It may also occur upon stopping antipsychotics.[2] The underlying mechanism is believed to involve dopamine.[2] When antidepressants are the cause, there is no agreement on the distinction between activation syndrome and akathisia.[11] Akathisia is often included as a component of activation syndrome.[11] However, the two phenomena are not the same since the former, namely antipsychotic-induced akathisia, suggests a known neuroreceptor mechanism (e.g., dopamine-receptor blockade).[11] Diagnosis is based on the symptoms.[2] It differs from restless leg syndrome in that akathisia is not associated with sleeping. However, despite a lack of historical association between restless leg syndrome and akathisia, this does not guarantee that the two conditions do not share symptoms in individual cases.[2]

If akathisia is caused by an antipsychotic, treatment may include switching to an antipsychotic with a lower risk of the condition.[2] The antidepressant mirtazapine, although paradoxically associated with the development of akathisia in some individuals, has demonstrated benefit,[5] as have diphenhydramine, trazodone, benzatropine, cyproheptadine, and beta blockers, particularly propranolol.[2][4][12]

The term was first used by Czech neuropsychiatrist Ladislav Haškovec, who described the phenomenon in 1901 long before the discovery of antipsychotics, with drug-induced akathisia first being described in 1960.[1] It is from Greek a-, meaning "not", and καθίζειν kathízein, meaning "to sit", or in other words an "inability to sit".[2]

Classification

[edit]

Akathisia is usually classified as a medication-induced movement disorder. It can also be considered a neuropsychiatric concern, however, as it can be experienced purely subjectively without apparent movement abnormalities.[2] Akathisia is generally associated with antipsychotics, but was previously described in Parkinson's disease and other neuropsychiatric disorders.[5] It can also present with the use of non-psychiatric medications, including calcium channel blockers, antibiotics, anti-nausea and anti-vertigo drugs.[5]

Signs and symptoms

[edit]

Symptoms of akathisia are often described in vague terms, such as feeling nervous, uneasy, tense, twitchy, restless, and unable to relax.[1] Reported symptoms also include insomnia, a sense of discomfort, motor restlessness, marked anxiety, and panic.[13] Symptoms have also been said to resemble symptoms of neuropathic pain similar to fibromyalgia and restless legs syndrome.[14] When caused by psychiatric drugs, akathisia usually disappears quickly once the medication is reduced or stopped. However, late-onset akathisia, or tardive akathisia, may persist for months or years after the medication is discontinued.[15]

When misdiagnosis occurs in antipsychotic-induced akathisia, more antipsychotics may be prescribed, potentially worsening the symptoms.[7][16] If not identified, akathisia symptoms can increase in severity and lead to suicidal thoughts, aggression and violence.[1][2]

Visible signs of akathisia include repetitive movements, such as crossing and uncrossing the legs and constant shifting from one foot to the other.[1] Other noted signs include rocking back and forth, fidgeting, and pacing.[7] However, not all observable restless motion is akathisia. For example, while mania, agitated depression, and attention deficit hyperactivity disorder may present like akathisia, movements resulting from them feel voluntary, rather than being due to restlessness.[17]

Jack Henry Abbott, who was diagnosed with akathisia, described the sensation in 1981 as: "You ache with restlessness, so you feel you have to walk, to pace. And then as soon as you start pacing, the opposite occurs to you; you must sit and rest. Back and forth, up and down you go … you cannot get relief …"[18]

Causes

[edit]

Medication-induced

[edit]
Medication related causes of akathisia
Category Examples
Antipsychotics[19] Haloperidol, amisulpride, risperidone, aripiprazole, lurasidone, ziprasidone
SSRIs[20] Fluoxetine,[20] paroxetine,[13] citalopram, sertraline[21]
Antidepressants Venlafaxine, tricyclics, trazodone, mirtazapine,[22] and brexpiprazole
Antiemetics Metoclopramide, prochlorperazine, droperidol
Drug withdrawal Antipsychotic withdrawal[2]
Serotonin syndrome[23] Harmful combinations of psychotropic drugs

Medication-induced akathisia is termed acute akathisia and is frequently associated with the use of antipsychotics.[15] Antipsychotics block dopamine receptors, but the pathophysiology is poorly understood. Even so, drugs with successful therapeutic effects in the treatment of medication-induced akathisia have provided additional insight into the involvement of other transmitter systems. These include benzodiazepines, β-adrenergic blockers, and serotonin antagonists. Another major cause of the syndrome is the withdrawal observed in drug-dependent individuals.[24]

Akathisia involves increased levels of the neurotransmitter norepinephrine, which is associated with mechanisms that regulate aggression, alertness, and arousal.[25] It has been correlated with Parkinson's disease and related syndromes, with descriptions of akathisia predating the existence of pharmacologic agents.[5]

Akathisia can be miscoded in side effect reports from antidepressant clinical trials as "agitation, emotional lability, and hyperkinesis (overactivity)"; misdiagnosis of akathisia as simple motor restlessness occurred, but was more properly classed as dyskinesia.[medical citation needed][13]

Diagnosis

[edit]

The presence and severity of akathisia can be measured using the Barnes Akathisia Scale,[26][27] which assesses both objective and subjective criteria.[26] Precise assessment of akathisia is problematic, as there are various types making it difficult to differentiate from disorders with similar symptoms.[5]

The primary distinguishing features of akathisia in comparison with other syndromes are primarily subjective characteristics, such as the feeling of inner restlessness and tension.[28][29] Akathisia can commonly be mistaken for agitation secondary to psychotic symptoms or mood disorder, antipsychotic dysphoria, restless legs syndrome, anxiety, insomnia, drug withdrawal states, tardive dyskinesia, or other neurological and medical conditions.[30]

The controversial diagnosis of "pseudoakathisia" is sometimes given.[1]

Treatment

[edit]

Acute akathisia induced by medication,[15] often antipsychotics, is treated by reducing or discontinuing the medication.[2][31] Low doses of the antidepressant mirtazapine may be of help.[5][32] Biperiden, an antipsychotic antidote, commonly used to improve acute extrapyramidal side effects related to antipsychotic drug therapy, is also used to treat akathisia. Benzodiazepines, such as lorazepam; beta blockers such as propranolol; anticholinergics such as benztropine; and serotonin antagonists such as cyproheptadine may also be of help in treating acute akathisia but are much less effective for treating chronic akathisia.[31] Vitamin B, and iron supplementation if deficient, may be of help.[2][4] Although they are sometimes used to treat akathisia, benzodiazepines and antidepressants can actually cause akathisia.[4]

Epidemiology

[edit]

Approximately one out of four individuals treated with first-generation antipsychotics develop akathisia.[5] Prevalence rates may be lower for modern treatment as second-generation antipsychotics carry a lower risk of akathisia.[31] In 2015, a French study found an overall prevalence rate of 18.5% in a sample of outpatients with schizophrenia.[33]

History

[edit]

The term was first used by Czech neuropsychiatrist Ladislav Haškovec, who described the phenomenon in a non-medication induced presentation in 1901.[34][1]

Reports of medication-induced akathisia from chlorpromazine appeared in 1954.[a] Later in 1960 there were reports of akathisia in response to phenothiazines (a related drug).[1] Akathisia is classified as an extrapyramidal side effect along with other movement disorders that can be caused by antipsychotics.[1]

In the former Soviet Union, akathisia-inducing drugs were allegedly used as a form of torture. Haloperidol, an antipsychotic medication, was used to induce intense restlessness and Parkinson's-type symptoms in prisoners.[36]

In 2020 clinical psychologist and professor of psychology Jordan Peterson was diagnosed with akathisia after being treated for insomnia and depression with benzodiazepines that was associated with an autoimmune disorder and was subsequently treated in Russia.[37][38]

See also

[edit]

Notes

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Akathisia

View on Grokipedia
from Grokipedia
Akathisia is a neuropsychiatric syndrome characterized by profound subjective inner restlessness and an irresistible urge to move, often accompanied by observable psychomotor agitation such as rocking, pacing, or leg-crossing, and is predominantly caused by blockade of dopamine D2 receptors in the basal ganglia and other neural pathways by antipsychotic medications. The condition manifests acutely within hours to weeks of initiating or escalating dopamine-antagonizing drugs, including typical antipsychotics like haloperidol and some atypicals like aripiprazole, though it can also appear in tardive or withdrawal forms persisting after discontinuation. Symptoms extend beyond mere anxiety or agitation, incorporating a dysphoric tension that drives compulsive movement, frequently leading to misdiagnosis as worsening psychosis, agitation, or voluntary hyperactivity, which perpetuates the underlying iatrogenic cause. Akathisia carries substantial risks, including severe psychological distress, impulsive aggression, and elevated suicide rates, with empirical evidence indicating it as a potentially life-threatening adverse effect that is systematically underrecognized in clinical practice despite its prevalence in up to 20-30% of antipsychotic-treated patients. Management prioritizes reducing or discontinuing the offending agent when feasible, supplemented by agents like propranolol or mirtazapine, though no intervention consistently resolves symptoms across cases, underscoring the need for vigilant monitoring and causal attribution over symptomatic palliation.

Definition and Classification

Core Definition

Akathisia is a neuropsychiatric syndrome characterized by an inability to remain still, manifesting as subjective inner restlessness accompanied by an irresistible urge to move. This condition involves both psychological discomfort, such as a sense of unease or dysphoria, and observable psychomotor agitation, distinguishing it from mere anxiety or agitation where movement is not primarily driven by physical compulsion. The term originates from the Greek words a- (without) and kathizein (to sit), literally denoting "inability to sit." According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), akathisia entails subjective complaints of restlessness, frequently paired with objective evidence of compelled movements like rocking, crossing and uncrossing legs, or pacing. It is classified among extrapyramidal movement disorders, which arise from dysfunction outside the corticospinal tracts, often linked to dopaminergic blockade in the basal ganglia. Unlike tardive dyskinesia, which features involuntary choreiform movements without inner drive, akathisia's core feature is the subjective awareness of restlessness prompting voluntary yet uncontrollable motion. Prevalence varies, but acute forms affect up to 20-30% of patients initiating antipsychotic therapy, underscoring its clinical significance as a potentially severe adverse effect. Untreated akathisia can exacerbate underlying psychiatric symptoms, increase suicide risk, and lead to treatment nonadherence due to its distressing nature.

Types and Subtypes

Akathisia is classified into several types based on temporal onset, duration, and clinical features, with acute and tardive forms being the most commonly recognized. Acute akathisia manifests shortly after initiating or escalating dopamine-blocking agents, such as antipsychotics, typically within the first two weeks of treatment, and is characterized by transient psychomotor restlessness that resolves upon dose reduction or medication discontinuation. In contrast, tardive akathisia emerges after prolonged exposure to these agents, often following months to years of therapy, and persists independently of ongoing treatment, resembling the chronicity of tardive dyskinesia due to sustained dopaminergic hypersensitivity. Chronic akathisia encompasses cases lasting more than six months, overlapping with tardive forms in extended duration but potentially arising from continuous low-level exposure to offending drugs like calcium channel blockers or antipsychotics. Withdrawal akathisia, also termed rebound akathisia, occurs upon abrupt reduction, discontinuation, or tapering of antipsychotics or anticholinergics, with symptoms intensifying within days to six weeks, driven by dopaminergic rebound rather than blockade. Pseudoakathisia represents a subtype distinguished by observable motor restlessness—such as leg swinging or pacing—without the patient's subjective awareness or distress of inner turmoil, often observed in chronic or tardive contexts among individuals with limited insight or cognitive impairment. This form highlights the dissociation between objective signs and subjective experience, complicating diagnosis as it may mimic stereotypic movements unrelated to akathisia's core phenomenology. Subacute variants, less distinctly categorized, bridge acute and chronic presentations with onset beyond two weeks but before tardive thresholds, though empirical delineation remains inconsistent across studies.

Signs and Symptoms

Subjective Symptoms

The subjective component of akathisia is characterized by an intense, often distressing sense of inner restlessness, typically described by patients as a compelling urge to move that arises from an uncomfortable internal tension or jitteriness. This sensation is frequently reported as difficult to articulate precisely, with patients conveying a subjective feeling of motor unrest that persists regardless of external circumstances and is only partially relieved by physical activity. Common patient-reported experiences include nervousness, a pervasive unease localized to the limbs or torso, and an overwhelming need to fidget, pace, or shift positions, which can intensify when attempting to remain sedentary. These symptoms often accompany heightened anxiety or panic, distinguishing akathisia from pure psychological agitation by their viscerally motoric quality, where stillness exacerbates the discomfort. In severe cases, the subjective distress may manifest as profound emotional turmoil, including irritability, depressive mood, or even suicidal ideation, attributed to the relentless and intolerable nature of the internal drive. Variability in symptom intensity is noted, with acute episodes potentially emerging within hours of causative exposure and chronic forms persisting as a gnawing, low-grade agitation that impairs daily functioning.

Objective Signs

Objective signs of akathisia are clinically observable motor disturbances reflecting an underlying compulsion to move, typically assessed during brief observation periods such as those used in standardized rating scales. These manifestations include semi-purposeful or purposeless movements, such as shuffling or tramping of the legs and feet while seated or standing, frequent shifting of body position in a chair, and difficulty remaining seated for extended periods. More pronounced objective features involve marked restlessness, characterized by intense and frequent changes in posture, repeated rising from a seated position, and pacing around the examination area. In severe cases, patients exhibit frank akathisia with constant pacing or an inability to remain seated or stand still for more than a few seconds, often accompanied by fidgetiness in the hands, arms, limbs, or trunk. Additional observable behaviors include rocking from foot to foot while standing, repetitive swinging of the legs or arms, complex stereotypic movements, and an inability to maintain stillness in supine positions. The Barnes Akathisia Rating Scale formalizes these observations in its objective item, scoring from 0 (normal, occasional fidgeting) to 3 (constant akathisia-related movements), providing a reliable measure for severity independent of patient self-report. These signs distinguish akathisia from pure subjective restlessness, though they often correlate with the intensity of underlying neuroleptic exposure.

Pathophysiology

Neurobiological Mechanisms

Akathisia arises primarily from the blockade of dopamine D2 receptors by antipsychotic medications, resulting in hypoactivity of dopaminergic transmission in the nigrostriatal pathway, which governs motor control, and the mesolimbic pathway, contributing to subjective restlessness and dysphoria. This relative dopamine deficiency disrupts striatal circuitry, particularly in the basal ganglia, where D2 receptor antagonism leads to extrapyramidal symptoms akin to parkinsonism but distinguished by prominent inner agitation. Preclinical evidence from primate models supports this, showing that D2 blockade in the ventral striatum correlates with akathisic behaviors, while compensatory upregulation of D2 receptors may occur with chronic exposure, potentially exacerbating tardive forms. An imbalance between dopaminergic hypoactivity and hyperactivity in noradrenergic and serotonergic systems further modulates akathisia, with noradrenergic excess in the basal ganglia implicated in the syndrome's dysphoric component. Serotonergic influences, via 5-HT2A receptor modulation, can indirectly suppress dopamine release in prefrontal and striatal regions, as seen with atypical antipsychotics that exhibit higher 5-HT2A affinity relative to D2 blockade. Cholinergic-serotonergic interactions in the nucleus accumbens shell also play a role, though akathisia's poor response to anticholinergics differentiates it from other dopamine-mediated extrapyramidal effects. Emerging evidence points to additional mechanisms, including GABAergic dysregulation influencing dopamine signaling and glutamatergic alterations via calcium channel disruptions, as suggested by the efficacy of agents like gabapentin that target α2δ subunits to normalize channel trafficking. In chronic cases, neuroimaging reveals hypo-perfusion in frontal and parietal regions, potentially reflecting sustained pathway dysfunction or secondary neuroinflammation impairing neurogenesis in dopaminergic circuits. These findings underscore akathisia's multifactorial neurobiology, beyond simple D2 antagonism, though definitive causal pathways remain incompletely elucidated due to reliance on indirect clinical and animal models.

Neurotransmitter Dysregulation

Akathisia arises predominantly from dysregulation of dopaminergic neurotransmission, wherein blockade of dopamine D2 receptors—particularly in the nigrostriatal pathway—by agents such as antipsychotics reduces dopaminergic activity, precipitating inner restlessness and compulsive movements. This effect intensifies with greater than 80% D2 receptor occupancy, disrupting striatal motor inhibition and ventral striatal dopamine depletion, which may trigger compensatory hyperactivity manifesting as dysphoria and agitation. In tardive forms, chronic blockade can induce D2 receptor upregulation and hypersensitivity, perpetuating symptoms even after discontinuation. Noradrenergic dysregulation interacts with dopaminergic deficits, as dopamine antagonism in the basal ganglia elevates norepinephrine outflow via feedback mechanisms, overactivating β1-adrenergic receptors in regions like the amygdala and nucleus accumbens to amplify psychomotor unrest. This imbalance underscores the utility of β-blockers like propranolol, which attenuate noradrenergic hyperactivity in animal models and clinical cases. Serotonergic pathways modulate these interactions; 5-HT2A receptor antagonism—prevalent in atypical antipsychotics—upregulates nigrostriatal dopamine release, thereby reducing akathisia risk relative to typical agents with predominant D2 effects. Conversely, enhanced serotonergic activity, as from selective serotonin reuptake inhibitors, inhibits nigrostriatal dopamine via indirect mechanisms, contributing to SSRI-induced akathisia. GABAergic transmission provides inhibitory counterbalance, with hypoactivity implicated in unchecked excitability; augmentation via GABAA-enhancing agents like gabapentin or pregabalin alleviates symptoms by bolstering neuronal inhibition and modulating calcium influx in affected pathways. These multifactorial dysregulations highlight akathisia's complexity beyond isolated dopamine blockade, involving interconnected neurotransmitter networks in motor and limbic circuits.

Causes

Medication-Induced Causes

The most frequent cause of akathisia is exposure to antipsychotic medications, which disrupt dopaminergic signaling in the nigrostriatal pathway, resulting in subjective inner restlessness and objective motor agitation. First-generation (typical) antipsychotics, such as haloperidol and chlorpromazine, exhibit the highest risk due to potent D2 receptor blockade, with acute akathisia incidence ranging from 5% to 45% depending on dose and patient factors like antipsychotic-naïve status. Second-generation (atypical) antipsychotics, including risperidone, aripiprazole, and lurasidone, pose a lower but still significant risk—typically 5% to 20%—as they exhibit partial agonism or weaker D2 affinity, though agents like aripiprazole have been linked to rates exceeding 10% in schizophrenia trials. Overall, antipsychotic-induced akathisia affects 14% to 35% of treated patients, often emerging within hours to days of initiation or dose escalation. Beyond antipsychotics, selective serotonin reuptake inhibitors (SSRIs) can precipitate akathisia through enhanced serotonergic activity that indirectly suppresses dopaminergic tone. Fluoxetine (Prozac) and sertraline (Zoloft), SSRI antidepressants, can induce akathisia as a known but uncommon extrapyramidal side effect. Symptoms involve inner restlessness and an intense, uncontrollable urge to move, often leading to pacing, fidgeting, purposeless movements (especially of legs and feet), and in some cases involving the hands (e.g., fidgeting or pressing). These effects are generally milder than neuroleptic-induced akathisia and may respond to dose reduction, propranolol, or discontinuation. Multiple case reports document sertraline-induced akathisia, often developing within days at typical doses (50-100 mg/day), with symptoms including severe restlessness, pacing, and inner tension, sometimes misdiagnosed as panic attacks or leading to self-harm. Key examples include a 1993 case of probable sertraline-induced akathisia in an 18-year-old woman , three cases in adults aged 37-48 who developed akathisia within 2-3 days at 50 mg/day and resolved after discontinuation or adjunctive propranolol or other agents , and a 2016 case of a 45-year-old man who developed severe akathisia after 6 days on sertraline (up to 100 mg/day), leading to a suicide attempt, resolved with discontinuation and propranolol . Case reports have documented severe episodes, including suicidal ideation, after starting drugs like escitalopram or fluoxetine. Antiemetics with dopamine antagonist properties, such as metoclopramide and prochlorperazine, induce akathisia via similar D2 blockade, particularly in acute settings like postoperative nausea management, where rates approach 20-30% with intravenous administration. Less commonly, other agents including certain antibiotics (e.g., azithromycin), calcium channel blockers, and lithium have been implicated, though evidence remains largely anecdotal or from isolated case series rather than large-scale trials. Risk factors amplifying medication-induced akathisia include rapid titration, high doses, polypharmacy, and individual vulnerabilities like female sex or concurrent substance use, underscoring the causal role of nigrostriatal dopamine hypersensitivity following blockade. Discontinuation or switching agents often resolves symptoms, but persistent forms (tardive akathisia) may endure post-exposure in 10-20% of chronic antipsychotic users.

Non-Pharmacological Causes

Akathisia can manifest in patients with idiopathic Parkinson's disease (PD) as a non-motor symptom attributable to underlying dopaminergic dysfunction in the basal ganglia, independent of antipsychotic or other dopamine-blocking medications. In a 1987 study interviewing 100 PD patients, 68% reported experiencing periodic akathisia, characterized by subjective restlessness and compulsive movements, often worsening during "off" periods of levodopa therapy but present prior to treatment initiation in some cases. A 1994 clinical evaluation of PD patients found that 45% met criteria for akathisia, with high interrater reliability (kappa = 0.89), suggesting it as a distinct feature of the disease rather than solely a treatment side effect. This association likely stems from endogenous dopamine depletion and nigrostriatal pathway degeneration, mirroring the neurobiological disruptions seen in drug-induced forms but arising from neurodegenerative processes. Akathisia in PD may contribute to gait disturbances, falls, and reduced quality of life, though it remains underrecognized compared to other extrapyramidal symptoms like bradykinesia. Other non-pharmacological etiologies are rare and poorly documented, with isolated reports linking cocaine abuse to akathisia-like symptoms via acute dopamine dysregulation, though such cases blur into substance-induced categories. No robust evidence supports idiopathic akathisia occurring de novo without underlying neurological pathology or substance exposure.

Diagnosis

Diagnostic Criteria

Akathisia is diagnosed clinically through the identification of subjective inner restlessness combined with objective psychomotor agitation, typically emerging in temporal association with antipsychotic or other dopamine-blocking medications. The core features include a compelling urge to move, often described by patients as an intolerable inner tension or discomfort that prompts repetitive movements such as leg crossing and uncrossing, foot tapping, or pacing, distinguishing it from mere anxiety-driven fidgeting. No laboratory tests, neuroimaging, or biomarkers are required or diagnostic, as the condition relies entirely on history and observation. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), characterizes medication-induced acute akathisia as subjective complaints of restlessness—frequently accompanied by observed excessive movements—coupled with a sense of inner drivenness or dysphoria, excluding cases attributable to the primary psychiatric condition or unrelated neurological disorders. This definition emphasizes the dual subjective-objective presentation, with symptoms often peaking within days to weeks of medication initiation or dose escalation. In the International Classification of Diseases, 11th Revision (ICD-11), akathisia is coded as 8A07.1 under secondary parkinsonism and other movement disorders, defined by persistent motor restlessness and inability to remain seated or still despite awareness of the purposelessness of the movements. Severity assessment commonly employs the Barnes Akathisia Rating Scale (BARS), a validated four-item tool developed in 1989 that quantifies symptoms on a 0-3 scale for objective akathisia (e.g., 0 = normal, 3 = marked inability to remain seated with frequent shifting or marching in place), subjective awareness of restlessness, subjective distress related to restlessness, and a global clinical impression (0-5 scale). A global score of 2 indicates mild akathisia, 3 moderate, and ≥4 severe or pseudoakathisia (objective signs without subjective complaint). The scale's reliability stems from its incorporation of diagnostic thresholds for pseudoakathisia and graded akathisia, aiding differentiation from comorbid conditions like tardive dyskinesia or exacerbation of underlying psychosis. Diagnosis requires exclusion of mimics such as restless legs syndrome (which lacks daytime motor restlessness), anxiety disorders (lacking the driven, stereotypic movements), or withdrawal states, often necessitating a trial reduction or discontinuation of the offending agent to confirm causality. Chronic akathisia, persisting beyond three months post-medication adjustment, follows similar criteria but may involve lower thresholds for subjective distress due to adaptation. Misdiagnosis as agitation occurs in up to 25% of cases in clinical settings, underscoring the need for targeted questioning about inner torment versus external anxiety.

Differential Diagnosis Challenges

Akathisia's diagnosis is frequently complicated by its symptomatic overlap with common psychiatric conditions, leading to underdiagnosis or misattribution to the underlying disorder. Symptoms such as inner restlessness and psychomotor agitation mimic manifestations of anxiety, psychotic agitation, mania, or agitated depression, prompting clinicians to interpret them as disease progression rather than an adverse effect. This overlap is exacerbated by the subjective nature of akathisia, where patients may describe distress in terms akin to anxiety without prominent objective motor signs, resulting in delayed recognition. Distinguishing akathisia from anxiety proves particularly challenging, as both involve fidgeting or restlessness, but akathisia features a compelling, semi-voluntary urge to move (e.g., leg crossing or pacing) driven by inner tension, whereas anxiety often presents with more generalized clumsiness or autonomic symptoms like lip smacking without relief from movement. Agitation associated with schizophrenia or bipolar disorder further confounds differentiation, as it shares purposeless movements but lacks akathisia's medication-induced etiology and specific dopaminergic blockade link. Misdiagnosis often leads to escalated antipsychotic dosing, intensifying akathisia and potentially precipitating severe outcomes like suicidality or aggression. Other movement disorders add to diagnostic hurdles: restless legs syndrome (RLS) involves nocturnal discomfort relieved by ambulation, contrasting akathisia's persistent daytime urge unrelieved by motion; tics are abrupt and suppressible but lack akathisia's sustained inner drive; and tardive dyskinesia features involuntary stereotypies rather than suppressible restlessness. Without specific biomarkers or consensus on neurobiological mechanisms, diagnosis relies on clinical scales like the Barnes Akathisia Rating Scale, yet clinician under-assessment and variable presentations—ranging from subtle subjective complaints to overt rocking—hinder prompt identification.
ConditionKey Distinguishing Features from Akathisia
AnxietyGeneralized fidgeting with autonomic arousal; no specific urge for patterned movement; psychological triggers predominant.
Psychotic AgitationPurposeless, whole-body hyperactivity tied to delusions/hallucinations; not suppressible or semi-voluntary.
Restless Legs SyndromeNocturnal exacerbation, sensory discomfort in legs relieved by walking; absent during day.
TicsSudden, repetitive, involuntary bursts (e.g., facial); briefly suppressible but stereotyped, not driven by inner restlessness.

Treatment and Management

Pharmacological Interventions

The primary pharmacological strategy for managing akathisia involves reducing the dose or discontinuing the causative agent, such as antipsychotics, when clinically feasible, as this addresses the underlying etiology and leads to resolution in many cases. If symptom persistence necessitates adjunctive therapy, non-selective beta-blockers like propranolol are recommended as first-line, with doses typically starting at 10-30 mg two to three times daily and titrating up to 80-120 mg/day, achieving response rates of approximately 64% for complete remission in antipsychotic-induced cases. Propranolol has also been shown to be effective in SSRI-induced akathisia, including cases precipitated by fluoxetine, often in conjunction with dose reduction or discontinuation of the offending SSRI. Propranolol's efficacy stems from blockade of peripheral beta-adrenergic receptors, mitigating subjective restlessness, though evidence from randomized trials is limited by small sample sizes and short durations. Mirtazapine, an antidepressant with noradrenergic and specific serotonergic activity, administered at low doses of 15 mg daily, has demonstrated superior efficacy in meta-analyses for antipsychotic-induced akathisia, outperforming several alternatives with favorable tolerability. Its mechanism likely involves antagonism at 5-HT2A and histamine receptors, reducing dopaminergic hypersensitivity without exacerbating psychosis. Rare cases of mirtazapine-induced akathisia have been reported. Anticholinergics such as biperiden or benztropine (1-2 mg as needed) show moderate efficacy in some reviews, particularly for objective motor symptoms, but randomized data indicate limited benefit for subjective components and potential inefficacy overall, prompting caution in routine use due to side effects like cognitive impairment. Benzodiazepines, including lorazepam (0.5-2 mg as needed) or clonazepam, provide symptomatic relief through GABAergic enhancement, suitable for acute agitation but with risks of dependence and sedation limiting long-term application; they rank moderately in network meta-analyses for akathisia improvement. Emerging evidence supports vitamin B6 (pyridoxine) at 600-1200 mg/day as highly effective with excellent tolerability, potentially via modulation of neurotransmitter synthesis, though larger trials are needed to confirm superiority over established agents. Other options like cyproheptadine (a 5-HT2 antagonist) or mianserin may be considered in refractory cases, but data remain inconsistent and secondary to primary interventions. Overall, treatment selection requires balancing efficacy against comorbidities, with no single agent universally effective due to akathisia's heterogeneous pathophysiology.

Non-Pharmacological Approaches

Non-pharmacological approaches to managing akathisia primarily serve as adjunctive strategies, given the limited high-quality evidence supporting their standalone efficacy. These interventions focus on symptom alleviation through behavioral and educational techniques, often integrated with pharmacological adjustments or dose reductions of causative agents. Evidence derives mainly from small-scale studies and clinical observations, emphasizing the need for further randomized controlled trials to establish robustness. Structured relaxation techniques have shown preliminary promise in reducing akathisia symptoms. In a case series of nine patients with schizophrenia and antipsychotic-induced akathisia, a 12-minute structured relaxation program—comprising four breathing exercises and six tension-relaxation exercises, delivered by trained professionals in group or individual sessions—yielded significant improvements on the Barnes Akathisia Rating Scale. Mean scores decreased from 3.3 at baseline to 1.4 immediately post-intervention and 1.0 at one-week follow-up (p=0.008 for baseline to follow-up comparison), with patients reporting subjective relief but requiring ongoing professional encouragement for self-administration. Limitations include the small sample size, absence of a control group, and potential confounding from concurrent medications, underscoring the approach's investigational status. Psychoeducation represents another non-pharmacological element, involving patient and caregiver instruction on akathisia's manifestations, triggers, and coping mechanisms to enhance adherence and mitigate distress. This strategy aims to foster awareness of treatment-emergent side effects, enabling proactive behavioral adjustments such as environmental modifications to accommodate restlessness without self-harm. Clinical reviews advocate its inclusion in comprehensive management plans, though empirical data on isolated outcomes remain sparse. Physical activity and relaxation practices, including light exercise or movement-based coping (e.g., structured walking or under-desk pedaling), may provide temporary outlets for motor restlessness, potentially reducing subjective urgency in select cases. However, evidence is anecdotal or derived from broader extrapyramidal symptom management, with reports of paradoxical worsening in some patients under antipsychotic regimens, necessitating individualized assessment to avoid exacerbation. Cognitive-behavioral techniques, while not specifically validated for akathisia, have been proposed to address associated anxiety or maladaptive responses, but lack dedicated trials confirming efficacy. Overall, these approaches underscore akathisia's subjective burden, prioritizing patient-centered symptom monitoring over curative intent.

Prognosis

Acute Akathisia Outcomes

Acute akathisia, characterized by the rapid onset of subjective restlessness and objective motor agitation following initiation or dose escalation of an offending agent such as antipsychotics, generally exhibits a favorable prognosis when identified promptly and the causative medication is discontinued or reduced. Symptoms typically resolve within days to weeks after intervention, with naturalistic studies indicating abatement in the majority of cases upon withdrawal of the precipitant. For instance, in patients treated with certain antipsychotics like cariprazine, median resolution time for akathisia following the last dose has been reported as approximately one week. Early management, including adjunctive therapies such as beta-blockers (e.g., propranolol) or anticholinergics, further improves outcomes by alleviating symptoms more rapidly than discontinuation alone, reducing the risk of treatment non-adherence. Vitamin B6 has demonstrated efficacy in randomized trials for acute neuroleptic-induced akathisia, with significant reductions in subjective restlessness compared to placebo within treatment periods. Mirtazapine also shows promise, with small-scale studies reporting response rates of up to 25% in antipsychotic-induced cases. Untreated or delayed recognition, however, correlates with adverse sequelae, including heightened patient distress, worsening of comorbid psychiatric symptoms, and increased likelihood of medication discontinuation, which can compromise overall therapeutic efficacy. Acute akathisia carries a low risk of progression to chronic forms if addressed swiftly, distinguishing it from tardive variants that may persist post-withdrawal. Incidence rates in acutely ill populations range from 42% to over 50% in the first month of antipsychotic exposure, underscoring the need for vigilant monitoring to optimize outcomes.

Chronic and Tardive Akathisia

Chronic akathisia refers to the persistence of akathisia symptoms for more than three months, often in the context of ongoing or recently adjusted antipsychotic therapy, distinguishing it from acute forms that resolve more readily with intervention. Tardive akathisia, a subtype associated with prolonged antipsychotic exposure, typically emerges with a delayed onset after one to three months of treatment and may continue or even intensify following drug discontinuation or dose reduction, akin to other tardive syndromes like tardive dyskinesia. Both forms manifest with subjective inner restlessness, an irresistible urge to move, and observable motor behaviors such as leg crossing, shifting postures, or pacing, primarily affecting the lower limbs, though chronic cases can involve broader jitteriness. Pathophysiologically, chronic akathisia likely stems from sustained dopaminergic dysregulation in the basal ganglia, exacerbated by long-term receptor blockade, while tardive akathisia may involve postsynaptic dopamine hypersensitivity, explaining its paradoxical worsening upon withdrawal. These variants are more prevalent in schizophrenia patients on maintenance antipsychotics, with chronic akathisia reported in up to 24% of such cohorts in older studies. Tardive akathisia occurs less frequently, comprising about 2.4% of tardive syndrome subtypes in clinical samples, and shows a higher incidence in older females. Prognosis for both is guarded compared to acute akathisia, with symptoms often refractory to standard treatments like beta-blockers or dose adjustments, persisting for months to years and contributing to treatment non-adherence, functional impairment, and reduced quality of life. Complete remission is uncommon, particularly for tardive forms, where low rates of spontaneous resolution (as seen in broader tardive syndromes) necessitate lifelong symptom management, though some improvement may occur with agents like clozapine or GABA modulators in select cases. Persistent symptoms heighten risks of psychiatric decompensation and secondary complications, underscoring the need for vigilant monitoring in long-term antipsychotic users.

Epidemiology

Prevalence and Incidence

The incidence of acute akathisia in patients treated with antipsychotic medications varies widely, with reported rates ranging from 8% to 76% for conventional neuroleptics, and a conservative estimate of 20% to 30%. A systematic review of antipsychotic-induced extrapyramidal side effects found a pooled prevalence of akathisia at 11% across studies involving various antipsychotics. In a cohort of 493 individuals with first-episode schizophrenia spectrum disorders initiating antipsychotic treatment, the overall incidence was 19.5%, with no significant differences linked to demographic or clinical variables at baseline. Tardive akathisia, which emerges after prolonged exposure (typically more than 3 months), is less common than acute forms, though specific incidence rates are underreported due to diagnostic challenges and overlap with tardive dyskinesia. Prevalence estimates for akathisia in long-term antipsychotic users are approximately 18.5% in some community-dwelling samples of patients with schizophrenia, often comorbid with other movement disorders. Specific prevalence estimates for tardive akathisia are underreported and generally lower. Factors such as higher doses, typical antipsychotics, and individual susceptibility (e.g., iron homeostasis alterations) elevate risk, contributing to variability across studies. In non-psychiatric settings, such as delirium management, akathisia prevalence is lower but still notable, with systematic reviews indicating higher rates in vulnerable patients receiving antipsychotics, though exact figures remain inconsistent due to underrecognition. Overall, akathisia remains predominantly iatrogenic, with negligible baseline incidence in untreated populations.

Risk Factors

The primary risk factor for akathisia is exposure to antipsychotic medications, particularly first-generation (typical) agents such as haloperidol, which carry a higher incidence of up to 45% compared to second-generation (atypical) antipsychotics. High-potency antipsychotics and rapid dose escalation further elevate the risk, with studies identifying current neuroleptic dose and rate of increment as significant predictors in prospective assessments of psychotic inpatients. Antipsychotic polypharmacy, including combinations of multiple second-generation agents or mixing with first-generation drugs, is associated with substantially increased prevalence, reaching 34% versus 11% for second-generation monotherapy. Certain second-generation antipsychotics, notably aripiprazole, risperidone, and asenapine, confer a comparatively higher risk among atypicals, as evidenced by comparative trials and meta-analyses showing elevated rates relative to low-risk options like olanzapine or clozapine. Akathisia typically emerges within the first two weeks of initiating or increasing antipsychotic therapy, underscoring the role of acute dopaminergic blockade in the basal ganglia and nucleus accumbens. Patient-specific factors include antipsychotic-naïve status or first-episode psychosis, where vulnerability is heightened due to lack of prior tolerance to extrapyramidal effects. Underlying psychiatric conditions such as schizophrenia or bipolar disorder independently contribute, with schizophrenia patients exhibiting 15-35% prevalence in community settings. Female sex and iron deficiency have been linked in case series and reviews, potentially exacerbating dopaminergic imbalance, while younger age shows an inverse association with risk in some cohorts. Prior extrapyramidal symptoms or affective disorders also predict development, based on multivariate analyses in neuroleptic-treated populations.

History

Early Observations

The earliest documented description of a syndrome resembling akathisia dates to the 17th century, when British physician Thomas Willis (1621–1675) observed restless leg symptoms characterized by an irresistible urge to move the limbs, disrupting sleep and causing discomfort, though he did not use the term akathisia and linked it to sensory disturbances rather than a distinct motor disorder. The term "akathisia," derived from Greek roots meaning "inability to sit," was formally introduced by Czech neuropsychiatrist Ladislav Haskovec on November 7, 1901, during a presentation at the Société de Neurologie in Paris, based on observations of two adult male patients exhibiting subjective restlessness and objective motor agitation. Haskovec described symptoms including an inability to remain seated for extended periods, a sensation of jumping or restlessness primarily in the legs, constant pacing with normal gait, generalized tremor (reported but not always observable), insomnia, vertigo, paraesthesias, and aches, without evident psychosis, neurological deficits, or organic pathology; he classified it as a nonorganic psychiatric condition akin to hysteria or neurasthenia. Subsequent early 20th-century observations expanded recognition beyond hysteria, with French neurologist Jean Athanase Sicard and German neurologist Robert Bing associating akathisia-like restlessness with parkinsonism in 1923, and British neurologist Samuel Kinnier Wilson applying the term to parkinsonian tremor and akinesia patients by 1940, highlighting its occurrence in basal ganglia disorders predating antipsychotic medications. These pre-pharmacological accounts emphasized akathisia as a subjective-objective syndrome of inner tension and compulsive movement, often misattributed to psychological origins due to limited neuroanatomical understanding at the time.

Key Developments in Recognition

The term akathisia, derived from Greek roots meaning "inability to sit," was first coined and described in 1901 by Czech neuropsychiatrist Ladislav Haškovec, who observed subjective inner restlessness and objective motor agitation in patients with hysteria and neurosis, independent of any pharmacological exposure. Haškovec's cases emphasized an irresistible urge to move, often manifesting as pacing or fidgeting, distinguishing it from mere anxiety. Subsequent early 20th-century reports linked similar symptoms to basal ganglia dysfunction, including post-encephalitic parkinsonism during the 1916–1928 encephalitis lethargica epidemic and idiopathic Parkinson's disease, where it was noted as a form of hyperkinesia complicating akinetic rigidity. Recognition advanced significantly in the mid-20th century following the introduction of dopamine-depleting agents like reserpine in the early 1950s and the first antipsychotic, chlorpromazine, in 1952–1954, which induced akathisia as a frequent extrapyramidal side effect in up to 20–45% of treated patients, often paradoxically exacerbating agitation in psychotic individuals. These drug-induced cases highlighted akathisia's dopaminergic etiology, with symptoms emerging acutely within days to weeks of initiation or dose escalation, prompting its classification within the extrapyramidal syndrome spectrum alongside dystonia and parkinsonism. By the late 1950s, systematic studies differentiated subjective distress (e.g., tormenting unease) from objective signs (e.g., rocking or leg-crossing), improving diagnostic specificity amid initial conflation with anxiety or worsening psychosis. Further developments in the 1960s included the identification of tardive akathisia, a persistent form emerging after months to years of chronic antipsychotic exposure and potentially worsening upon drug withdrawal, first reported in 1960 as a late-onset variant resistant to standard treatments. This subtype underscored risks of long-term neuroleptic use, with prevalence estimates reaching 10–20% in prolonged therapy cohorts, influencing evolving guidelines for monitoring and dosage minimization. Diagnostic scales, such as the Barnes Akathisia Rating Scale introduced in 1982, later formalized assessment by quantifying severity across subjective, objective, and global dimensions, enhancing recognition in clinical trials and practice.

Controversies and Criticisms

Underrecognition in Clinical Practice

Akathisia remains frequently underrecognized in clinical practice despite being the most common drug-induced extrapyramidal side effect of antipsychotic medications. Clinicians often misdiagnose it as anxiety, agitation, or worsening of the underlying psychiatric condition, leading to erroneous dose escalations that intensify symptoms. In one analysis, underdiagnosis stems from clinician oversight in evaluating subjective restlessness and overreliance on objective motor signs, compounded by patients' challenges in describing internal discomfort. Common misattributions include conflating akathisia with psychotic excitement, restless legs syndrome, substance withdrawal, or even tardive dyskinesia, particularly in settings without systematic screening. The absence of laboratory or imaging diagnostics exacerbates this, as identification depends solely on clinical history and observation, often overlapping with primary psychiatric symptoms like those in schizophrenia or bipolar disorder. Prevalence estimates in schizophrenia patients range from 15% to 35% in community settings, yet routine assessment is rare, contributing to persistent oversight. Underrecognition carries severe risks, including treatment nonadherence, symptom exacerbation, relapse, aggression, and heightened suicidality, as untreated akathisia amplifies impulsivity and distress. Validated tools such as the Barnes Akathisia Rating Scale can mitigate this by enabling objective evaluation before and during antipsychotic initiation, though adoption remains inconsistent. Improved training on subjective components and interprofessional collaboration between psychiatrists and neurologists is advocated to address these gaps. Akathisia has been associated with increased risk of suicidal ideation and attempts in multiple case reports and observational studies, often exhibiting a temporal onset concurrent with the emergence of the syndrome. For instance, two cases documented impulsive suicide attempts where suicidal ideation arose suddenly alongside akathisia symptoms induced by neuroleptic treatment, resolving after symptom alleviation. Similarly, a case of escitalopram-induced severe akathisia in a 25-year-old male led to a suicide attempt, with symptoms remitting fully upon discontinuation and propranolol administration. In patients with first-episode schizophrenia, clinician-observed akathisia correlated significantly with suicidal ideation, alongside factors like depressed mood and younger age. Akathisia ratings also showed positive associations with Hamilton Depression Scale scores for suicidality and agitation in major depressive disorder patients. Evidence further indicates akathisia as a risk factor for suicidality in early psychosis, with studies identifying it—along with younger age and early illness onset—as predictive of treatment-emergent suicidal events. Antidepressant-related akathisia, such as from fluoxetine or sertraline, has been implicated in self-harm and suicidal behavior, potentially through dysphoric extrapyramidal reactions precipitating ideation. For instance, a 2016 case report described a 45-year-old man who developed severe akathisia six days after initiating sertraline at 50 mg/day (increased to 100 mg/day), resulting in a suicide attempt by overdose due to overwhelming restlessness; the symptoms resolved following sertraline discontinuation and propranolol administration. However, systematic reviews of antipsychotic-induced akathisia have concluded that while associations exist, a reliable causal link to suicidal behavior cannot be established across broader populations, highlighting challenges in distinguishing akathisia's direct role from underlying psychiatric conditions. Regarding violence, akathisia demonstrates links to aggressive, self-injurious, and homicidal behaviors, supported by observational data and forensic analyses. An early study observed heightened violence in patients experiencing akathisia compared to those without, suggesting the inner torment drives impulsive acts. Quantitative analyses confirm relationships between akathisia severity and both aggression and self-injury in neuropsychiatric cohorts. Case series of antidepressant-induced akathisia include instances of homicide, with eight documented cases of extreme violence or killing, often in individuals with genetic vulnerabilities like CYP450 polymorphisms impairing drug metabolism, leading to akathisia-related agitation and ideation. These events typically abate upon medication adjustment, underscoring akathisia's potential as a reversible precipitant distinct from delusion-driven violence. Comprehensive reviews emphasize akathisia's role in precipitating such outcomes, though underdiagnosis may confound prevalence estimates.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK519543/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC6299189/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC5771055/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC3670081/
  5. https://pubmed.ncbi.nlm.nih.gov/35696611/
  6. https://www.tandfonline.com/doi/full/10.2147/NDT.S337785
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC10921255/
  8. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2815790
  9. https://pubmed.ncbi.nlm.nih.gov/30137828/
  10. https://www.jneuropsychiatry.org/peer-review/successful-management-of-haloperidol-induced-akathisia-with-cyproheptadine.pdf.pdf
  11. https://pubmed.ncbi.nlm.nih.gov/26683525/
  12. https://my.clevelandclinic.org/health/diseases/23954-akathisia
  13. https://www.racgp.org.au/afp/2017/may/beyond-anxiety-and-agitation-a-clinical-approach-t
  14. https://pubmed.ncbi.nlm.nih.gov/10646622/
  15. https://www.cambridge.org/core/journals/cns-spectrums/article/clinical-challenges-of-akathisia/666A3F2C382C7A928C5029703B11DD18
  16. https://www.dovepress.com/the-relationship-between-antipsychotic-induced-akathisia-and-suicidal--peer-reviewed-fulltext-article-NDT
  17. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2021.728265/full
  18. https://pubmed.ncbi.nlm.nih.gov/12439833/
  19. https://www.cureus.com/articles/396602-aripiprazole--and-lurasidone-induced-akathisia-a-case-report-and-literature-review
  20. https://www.mdpi.com/2073-4425/14/3/616
  21. https://projectteachny.org/app/uploads/2017/09/Barnes_akathisia_scale.pdf
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC5516628/
  23. https://pubmed.ncbi.nlm.nih.gov/2574607/
  24. https://pubmed.ncbi.nlm.nih.gov/34337722/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC7457694/
  26. https://www.europeanreview.org/wp/wp-content/uploads/4746-4756.pdf
  27. https://pubmed.ncbi.nlm.nih.gov/9694033/
  28. https://accpjournals.onlinelibrary.wiley.com/doi/abs/10.1002/phar.2404
  29. https://pubmed.ncbi.nlm.nih.gov/8494087/
  30. https://psychiatry-psychopharmacology.com/index.php/pub/article/view/101
  31. https://www.psychiatrist.com/pcc/self-harm-in-sertraline-induced-akathisia/
  32. https://journals.lww.com/inpj/fulltext/2019/28020/escitalopram_induced_severe_akathisia_leading_to.24.aspx
  33. https://casereports.bmj.com/content/12/9/e229714
  34. https://pubmed.ncbi.nlm.nih.gov/3822142/
  35. https://www.neurology.org/doi/10.1212/WNL.37.3.477
  36. https://pubmed.ncbi.nlm.nih.gov/7990849/
  37. https://movementdisorders.onlinelibrary.wiley.com/doi/abs/10.1002/mds.870090507
  38. https://tjn.org.tr/full-text-pdf/115/eng
  39. https://www.findacode.com/icd-11/code-1975710133.html
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC10453030/
  41. https://www.sciencedirect.com/topics/medicine-and-dentistry/barnes-akathisia-scale
  42. https://psychiatryonline.org/doi/10.1176/appi.ajp.2007.07071150
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC9475911/
  44. https://www.droracle.ai/articles/320655/dose-recomendations-for-treatment-of-akathesia
  45. https://pubmed.ncbi.nlm.nih.gov/1932404/
  46. https://pubmed.ncbi.nlm.nih.gov/2549018/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC8374932/
  48. https://psychiatryonline.org/doi/full/10.1176/appi.pn.2024.06.6.3
  49. https://academic.oup.com/schizophreniabulletin/advance-article/doi/10.1093/schbul/sbae098/7692844
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC4676224/
  51. https://pubmed.ncbi.nlm.nih.gov/20124786/
  52. https://www.mdedge.com/currentpsychiatry/article/251237/mixed-topics/page/0/2
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC5958332/
  54. https://www.cambridge.org/core/journals/cns-spectrums/article/comparative-efficacy-of-akathisia-treatments-a-network-metaanalysis/AE602E0809CB910C7930FFFAC08933A5
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC2877608/
  56. https://www.rupahealth.com/post/what-is-akathisia-symptoms-causes-and-treatments
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC8293348/
  58. https://pubmed.ncbi.nlm.nih.gov/33915374/
  59. https://pubmed.ncbi.nlm.nih.gov/15554771/
  60. https://pubmed.ncbi.nlm.nih.gov/26557987/
  61. https://pubmed.ncbi.nlm.nih.gov/30443794/
  62. https://www.cpn.or.kr/view.html?uid=1541&vmd=Full
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC4219112/
  64. https://academic.oup.com/schizophreniabulletin/article/21/3/431/1943937
  65. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0257129
  66. https://pubmed.ncbi.nlm.nih.gov/28567698/
  67. https://www.sciencedirect.com/science/article/abs/pii/S0920996415300402
  68. https://pubmed.ncbi.nlm.nih.gov/7979885/
  69. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/akathisia
  70. https://journals.sagepub.com/doi/pdf/10.1177/014107688507800910
  71. https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/ladislav-haskovec-and-akathisia-100th-anniversary/FBB200E72E666A2B9012111EDE78F119
  72. https://pubmed.ncbi.nlm.nih.gov/7547643/
  73. https://www.medlink.com/articles/akathisia
  74. https://www.sciencedirect.com/topics/neuroscience/akathisia
  75. https://coreem.net/core/akathisia/
  76. https://pubmed.ncbi.nlm.nih.gov/3976927/
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC7660001/
  78. https://pubmed.ncbi.nlm.nih.gov/22926606/
  79. https://pubmed.ncbi.nlm.nih.gov/11514639/
  80. https://pubmed.ncbi.nlm.nih.gov/22614116/
  81. https://pubmed.ncbi.nlm.nih.gov/9333553/
  82. https://pubmed.ncbi.nlm.nih.gov/34887662/
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC8651045/
  84. https://pubmed.ncbi.nlm.nih.gov/1973544/
  85. https://pubmed.ncbi.nlm.nih.gov/24926584/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC3513220/
  87. https://www.sciencedirect.com/science/article/pii/S1752928X16300051
  88. https://psychiatryonline.org/doi/full/10.1176/jnp.13.3.336
Add your contribution
Related Hubs
User Avatar
No comments yet.